Vancomycin-resistant enterococcal urinary tract infections

Pharmacotherapy

Volumn 30, Issue 11, 2010, Pages 1136-1149

  Heintz, Brett H ^a,b   Halilovic, Jenana ^b,c   Christensen, Cinda L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c School of Pharmacy   (United States)

Author keywords

Ampicillin; Antimicrobials; Bacterial resistance; Daptomycin; Fosfomycin; Linezolid; Nitrofurantoin; Urinary tract infection; UTI; Vancomycin; Vancomycin resistant enterococci; VRE

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CORTICOSTEROID; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FOSFOMYCIN; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINEZOLID; NITROFURANTOIN; PENICILLIN G; PIPERACILLIN; QUINOLONE DERIVATIVE; STREPTOMYCIN; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLITIS; CREATININE BLOOD LEVEL; CYSTITIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG URINE LEVEL; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; INFECTION RISK; LOW DRUG DOSE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PYELONEPHRITIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VEIN DISEASE; VENOUS IRRITATION;

ALGORITHMS; ANIMALS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; ENTEROCOCCUS; EVIDENCE-BASED MEDICINE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; URINARY TRACT INFECTIONS; VANCOMYCIN RESISTANCE;

EID: 78149385778     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.11.1136     Document Type: Review

References (74)

1. Reik R, Tenover FC, Klein E, McDonald LC. The burden of vancomycin-resistant enterococcal infections in U.S. hospitals, 2003-2004. Diagn Microbiol Infect Dis 2008;62:81-5.
2. Drees M, Snydman DR, Schmid CH, et al. Prior environmental contamination increases the risk of acquisition of vancomycin-resistant enterococci. Clin Infect Dis 2008;46:678-85. (Pubitemid 351321550)
3. Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009;30:184-6.
4. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58:163-70.
5. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
6. Zhanel GG, Laing NM, Nichol KA, et al. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American vancomycin resistant enterococci susceptibility study (NAVRESS). J Antimicrob Chemother 2003;52:382-8.
7. Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996;156:2579-84.
8. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40:643-54.
9. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50:625-63.
10. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 2001;7:183-7.
11. Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 2008;52:2256-9.
12. Werner G, Gfrorer S, Fleige C, Witte W, Klare I. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 2008;61:1182-3.
13. Fraher MH, Corcoran GD, Creagh S, Feeney E. Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin. J Hosp Infect 2007;65:376-8.
14. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52:2383-8.
15. Iannini PB, Ehret J, Eickhoff TC. Effects of ampicillin-amikacin and ampicillin-rifampin on enterococci. Antimicrob Agents Chemother 1976;9:448-51.
16. Woodford N, Johnson AP, Morrison D, Speller DC. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995;8:585-615.
17. Werner G, Coque TM, Hammerum AM, et al. Emergence and spread of vancomycin resistance among enterococci in Europe [online exclusive article]. Euro Surveill 2008;13(47):pii=19046. Available from http://www.eurosurveillance. org/ViewArticle.aspx?ArticleId=19046.
18. Center for Disease Control and Prevention. Information for the public about VRE, 2008. Available from http://www.cdc.gov/ncidod/dhqp/ar-VRE-publicFAQ. html. Accessed April 20, 2010.
19. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003;51(suppl 3):iii13-21.
20. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance: recommendations of the hospital infection control practices advisory committee (HICPAC). Am J Infect Control 1995;23:87-94.
21. Sobel JD, Kaye D. Urinary tract infection. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 7th ed. Philadelphia, PA: Elsevier Inc., 2010:957-86.
22. Karanfil LV, Murphy M, Josephson A, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195-200.
23. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686-707.
24. Wong AH, Wenzel RP, Edmond MB. Epidemiology of bacteriuria caused by vancomycin-resistant enterococci: a retrospective study. Am J Infect Control 2000;28:277-81.
25. Johnson JR, Stamm WE. Diagnosis and treatment of acute urinary tract infections. Infect Dis Clin North Am 1987;1:773-91.
26. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-58.
27. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-40.
28. Hooton TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996;335:468-74.
29. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062-6.
30. White GW, Malow JB, Zimelis VM, Pahlavanzadeh H, Panwalker AP, Jackson GG. Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside. Antimicrob Agents Chemother 1979;15:540-3.
31. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 20th informational supplement: Enterococcus species. Wayne, PA: Clinical and Laboratory Standards Institute, 2010:76-8.
32. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of gram-negative and gram-positive organisms: tigecycline evaluation and surveillance trial 2004-2007. Diagn Microbiol Infect Dis 2009;65:288-99.
33. Perri MB, Hershberger E, Ionescu M, Lauter C, Zervos MJ. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002;42:269-71.
34. Sader HS, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from U.S. medical centers: results of the daptomycin surveillance program (2007-2008). Diagn Microbiol Infect Dis 2009;65:158-62.
35. Amsden GW. Table of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia, PA: Elsevier, Inc., 2010:705-61.
36. Thomson Micromedex. Micromedex 2.0 healthcare series: DRUGDEX system - 2010. Greenwood Village, CO: Thomson Micromedex, 2010.
37. Williamson JC, Craft DW, Butts JD, Raasch RH. In vitro assessment of urinary isolates of ampicillin-resistant enterococci. Ann Pharmacother 2002;36:246-50.
38. Cole M, Ridley B. Absence of bioactive metabolites of ampicillin and amoxycillin in man. J Antimicrob Chemother 1978;4:580-2.
39. Shrestha NK, Chua JD, Tuohy MJ, et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis 2003;35:12-14.
40. Borner K, Borner E, Lode H. Determination of linezolid in human serum and urine by high-performance liquid chromatography. Int J Antimicrob Agents 2001;18:253-8. (Pubitemid 32979198)
41. Bearden DT. Clinical pharmacokinetics of quinupristin/dalfopristin. Clin Pharmacokinet 2004;43:239-52.
42. Fisher L, North D. Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections. Int J Antimicrob Agents 2009;33:493-4.
43. Shea K, Hilburger E, Baroco A, Oldfield E. Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy. Ann Pharmacother 2008;42:722-5.
44. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-9. (Pubitemid 44527494)
45. Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycinresistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009;29:792-9.
46. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (≥ 8 mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211-19.
47. Shrestha NK, Amuh DA, Goldman MP, Riebel WJ, Tomford JW. Treatment of a complicated vancomycin resistant enterococcal urinary tract infection with fosfomycin. Infect Dis Clin Practice 2000;9:368-71.
48. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111:e394-434.
49. Oill PA, Kalmanson GM, Guze LB. Rifampin, ampicillin, streptomycin, and their combinations in the treatment of enterococcal pyelonephritis in rats. Antimicrob Agents Chemother 1981;20:491-2.
50. Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 1977;22:364-70.
51. Weinstein MP. Comparative evaluation of penicillin, ampicillin, and imipenem MICs and susceptibility breakpoints for vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Clin Microbiol 2001;39:2729-31.
52. Shungu DL, Cerami AT, Weinberg E, Capizzi T, Gadebusch HH. Tentative interpretive criteria for in vitro antibacterial susceptibility testing with imipenem. J Clin Microbiol 1986;23:421-4. (Pubitemid 16137730)
53. Jones RN. Prediction of enterococcal imipenem susceptibility using ampicillin or penicillin MICs: more evidence for a class concept. J Clin Microbiol 2001;39:3810-11.
54. Chambers HF. Penicillins and β-lactam inhibitors. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 7th ed. Philadelphia, PA: Elsevier Inc., 2009:309-22.
55. Cubist Pharmaceuticals, Inc. Cubicin (daptomycin) package insert. Lexington, MA; 2010. Available from http://www.cubicin.com/pdf/ PrescribingInformation.pdf. Accessed April 20, 2010.
56. Cantoni L, Glauser MP, Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 1990;34:2348-53.
57. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007;54:567-71.
58. Lucet JC, Armand-Lefevre L, Laurichesse JJ, et al. Rapid control of an outbreak of vancomycin-resistant enterococci in a French university hospital. J Hosp Infect 2007;67:42-8.
59. Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 2005;6:2315-26.
60. Nichol KA, Sill M, Laing NM, Johnson JL, Hoban DJ, Zhanel GG. Molecular epidemiology of urinary tract isolates of vancomycin-resistant Enterococcus faecium from North America. Int J Antimicrob Agents 2006;27:392-6.
61. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S133-45.
62. Butt T, Leghari MJ, Mahmood A. In vitro activity of nitrofurantoin in Enterococcus urinary tract infection. J Pak Med Assoc 2004;54:466-9.
63. Chaudhary U, Shamma M, Yadav A. Antimicrobial susceptibility patterns of common and unusual Enterococcus species isolated from clinical specimens. J Infect Dis Antimicrob Agents 2007;24:55-62.
64. Linden P, Kusne S, Pasculle AW. Susceptibility trends of conventional agents for the treatment of vancomycin-resistant enterococcal infection [abstract]. In program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1999:644.
65. Brown DF, Hope R, Livermore DM, et al. Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-6. J Antimicrob Chemother 2008;62(suppl 2):ii75-85.
66. Kunin CM, Dornbush AC, Finland M. Distribution and excretion of four tetracycline analogues in normal young men. J Clin Invest 1959;38:1950-63.
67. Howe RA, Robson M, Oakhill A, Cornish JM, Millar MR. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus. J Antimicrob Chemother 1997;40:144-5. (Pubitemid 27341652)
68. Aeschlimann JR, Zervos MJ, Rybak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrob Agents Chemother 1998;42:2710-17.
69. Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46:1319-24.
70. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518-24.
71. Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J Clin Microbiol 2008;46:1892-3.
72. Nicolle LE. Catheter-related urinary tract infection. Drugs Aging 2005;22:627-39.
73. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329:1328-34.
74. National Institute on Disability and Rehabilitation Research. The prevention and management of urinary tract infections among people with spinal cord injuries: National Institute on Disability and Rehabilitation Research consensus statement, January 27-29, 1992. J Am Paraplegia Soc 1992;15:194-204.